Verrica Q2 net income $0.2M; YCANTH units +32.8% QoQ; Nasdaq compliance regained

Verrica Pharmaceuticals Inc.

2025-Q2 EPS reported -$1.01 vs consensus -$0.72 ▼ miss (-40.5%)

Q2 product revenue $4.5M; license & collaboration revenue $8.2M (incl. $8.0M Torii milestone). Net income $0.2M ($0.02 GAAP EPS) vs net loss $17.2M YoY.
YCANTH dispensed applicator units 13,434, sequential growth of 32.8% over Q1'25. Revenue net $4.5M up 32.5% sequentially.
Regained Nasdaq bid price compliance after 1-for-10 reverse stock split on July 24, 2025.
Torii accelerated $8M milestone payment received July 2025; additional $10M milestone upon Japanese YCANTH approval expected by end of 2025.
Completed End-of-Phase 2 meeting with FDA for VP-315 (basal cell carcinoma); preparing Phase 3 program and exploring non-dilutive funding.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.